Conference Coverage

Use of Adjuvant Chemotherapy In Stage III Colon Cancer: Analysis of National and VA Nebraska-Western Iowa Health Care System Data Using National Cancer Database

Upadhyay S, Dahal S, Silberstein PT.

Abstract 33: 2014 AVAHO Meeting


 

Purpose: The National Comprehensive Cancer Network recommends chemotherapy for all stage III colon cancer patients. In fact, the American Society of Clinical Oncology quality program and the American College of Surgeons use administration of chemotherapy in stage III colon cancer as a quality measure. Though adjuvant chemotherapy improves overall survival in stage III colon cancer, prior studies have shown that it is underused. Its use was reported around 60%, with the use lower in females, the elderly, and African Americans. Our study uses a larger patient population from more recent years. We also analyzed different factors that may influence its use, including insurance type.

Methods: This is a retrospective study of stage 3 colon cancer patients diagnosed nationwide (n = 207,718) as well as at VA Nebraska-Western Iowa Health Care System (n = 10) in the National Cancer Data Base (NCDB). While the national data were available between 2000 and 2011, the data from the VAMC were available for 2010 and 2011. The NCDB contains about 70% of new cancer diagnosis in the U.S., deriving its data from > 1,500 American College of Surgeons-accredited cancer programs. Chi-square test was used to determine any difference in characteristics of patients who did or did not receive chemotherapy.

Results: One-fourth of all colon cancer patients at the VAMC were in stage III. Ninety percent of these patients received adjuvant chemotherapy. Nationwide, only 65% of such patients received adjuvant chemotherapy, with its use lower in elderly patients, whites, females, patients with one or more comorbidities, those with longer travel to treatment facility, and those with Medicare insurance, lower education, and lower income levels (all P < .05). Nonwhite and uninsured were more likely to be aged < 60 years.

Conclusions: This is the largest study to determine the use of chemotherapy in stage III colon cancer, both nationally and at local VAMC. Though its use nationwide has increased in recent years, the overall use is still low. Patient characteristics such as age, race, and gender, as well as socioeconomic factors influence its use. These findings have important implications for health care reform.

Recommended Reading

Metabolic Syndrome May Worsen Prognosis in Colorectal Cancer
AVAHO
Is Anemia a Reliable Clue to Colorectal Cancer?
AVAHO
Colorectal Cancer Screening: VA Providers' Attitudes and Practices
AVAHO
Breaking Down Barriers to Colorectal Cancer Screening
AVAHO
NSAIDs and Colorectal Risk: The Other Side
AVAHO
Combination Chemotherapy for Elders with Colorectal Cancer
AVAHO
Fast Facts: Metastatic Colorectal Cancer
AVAHO
Physician Nonadherence to Repeat Colonoscopy Guidelines for Screening and Polyp Surveillance in an Integrated Managed Care System
AVAHO
Endorectal Ultrasound (ERUS): Improving Veteran Patient Care and Outcomes While Streamlining Preoperative Evaluation in Rectal Cancer
AVAHO
One Veterans Affairs Medical Center’s Experience with Colorectal Carcinoma
AVAHO